Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Buspirone in the treatment of levodopa induced dyskinesias.

Literature DB >> 2056334

Buspirone in the treatment of levodopa induced dyskinesias.

B Kleedorfer, A J Lees, G M Stern.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1991 PMID： 2056334 PMCID： PMC488507 DOI： 10.1136/jnnp.54.4.376-a

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

× No keyword cloud information.

3 in total

Review 1. The modern management of Parkinson's disease.

Authors: N Quinn
Journal: J Neurol Neurosurg Psychiatry Date: 1990-02 Impact factor: 10.154

2. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.

Authors: D Tarsy; J D Parkes; C D Marsden
Journal: J Neurol Neurosurg Psychiatry Date: 1975-04 Impact factor: 10.154

3. Buspirone: chemical profile of a new class of anxioselective agents.

Authors: D L Temple; J P Yevich; J S New
Journal: J Clin Psychiatry Date: 1982-12 Impact factor: 4.384

3 in total

15 in total

Review 1. Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.

Authors: Yan A Ivanenkov; Mark S Veselov; Nina V Chufarova; Alexander G Majouga; Anna A Kudryavceva; Alexandre V Ivachtchenko
Journal: Mol Divers Date: 2015-05-09 Impact factor: 2.943

Review 2. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors: Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal: Nat Rev Drug Discov Date: 2018-09-28 Impact factor: 84.694

3. A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

Authors: Ruth B Schneider; Peggy Auinger; Christopher G Tarolli; Julia Iourinets; María Cristina Gil-Díaz; Irene H Richard
Journal: Parkinsonism Relat Disord Date: 2020-10-13 Impact factor: 4.891

Review 4. Drug-induced movement disorders.

Authors: F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal: Drug Saf Date: 1997-03 Impact factor: 5.606

Buspirone in the treatment of levodopa induced dyskinesias.

Review 1. The modern management of Parkinson's disease.

2. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.

3. Buspirone: chemical profile of a new class of anxioselective agents.

Review 1. Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.

Review 2. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

3. A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability.

Review 4. Drug-induced movement disorders.

Review 5. Methods of managing levodopa-induced dyskinesias.

6. Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.

Review 7. Non-dopaminergic treatments for motor control in Parkinson's disease.

Review 8. The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

9. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.

10. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.